Fortress Biotech Reports Q2 2024 Financial Highlights
Fortress Biotech reveals Q2 2024 financials with key FDA updates; NDA and BLA filings signal growth in dermatology and oncology.
- Latest
- Trending
Fortress Biotech reveals Q2 2024 financials with key FDA updates; NDA and BLA filings signal growth in dermatology and oncology.
IO Biotech's Q2 2024 EPS beats estimates, reporting -31 cents vs. expected -35 cents, despite no revenue.
BP's tech could explore Mars or Moon post NASA deal, sharing expertise from hostile environments.
Cognitive technology tested in space on TES-11 to automate satellite communications without human interaction.
New GhostWrite CPU bug allows attackers to access and control T-Head devices, affecting security and performance.
Manufacturers enhance quality assurance and training using XR technology, bridging workforce skill gaps.
Discover how technology addresses food insecurity through innovative solutions and sustainable business models.
Researchers discover vulnerabilities in Azure's AI Health Bot, raising security concerns for sensitive data access.
Lilly's new Boston facility enhances RNA/DNA research, hosting 500 scientists and expanding Gateway Labs to the East Coast.
Apple's Vision Pro headset marks a significant start in VR, with strong sales forecasts and a focus on both business ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.